Avastin Assessments

Which of the following Proto-onco genes are more commonly located in CRC?

• KRAS
• SMAD4
• P-53
• None of the above

What is the ideal treatment option for stage III (Duke C) CRC?

• Surgery Only
• Chemotherapy only
• Radiation only
• Surgery + adjuvant Chemotherapy

Which one of these regimen can be used irrespective of KRAS?

• CAPOX
• CAPOX + Panitumumab
• FOLFIRI + Cituximab
• Both B & C

BEVACIZUMAB- 1st Line Dosage in Colon Cancer -

• 5 mg/kg/2 weeks OR 7.5 mg/kg/3 weeks
• 5 mg/kg or 10 mg/kg/2 weeks OR 7.5 mg/kg or 15 mg/kg/3 weeks
• None of teh above

Patient population selcted in BRiTEa Trial - Bevacizumab beyond progression in routine oncology practiceP

• BEV + standard first-line CT (either oxaliplatin or irinotecan-based)
• Previously untreated, unresectable mCRC
• None of these

Bevacizumab acts by

• Binding the vascular endothelial growth factor (VEGF)
• Binding with the vascular endothelial growth factor receptor (VEGFR)
• Binding Epithelial Growth Factor (EGF)
• Binding Epithelial growth factor receptor (EGFR)

In CALGB trial the overall survival in Cetuximab arm Vs Bevacizumab arm was

• 13 Vs 18 months
• 24 Vs 28 months
• 29.9 Vs 29 months
• 33 Vs 35.2 months

Treatment arms in CALGB study were-

• Bevacizumab vs Cetuximab
• Bev+ chemo vs Cetuxi vs chemo
• Bev vs Chemo

____________ is the most common type of NSCLC.

• Adenocarcinoma
• Squamous cell carcinoma
• Large cell carcinoma

Bevacizumab Dosage & Administration - Unresectable, advanced, metastatic or mNSCLC Cisplatin based

• 7.5 mg/kg/3 weeks upto 6 cycles in combination followed by single agent
• 15 mg/kg/3 weeks upto 6 cycles in combination followed by single agent
• 5 mg/kg/5 weeks upto 12 cycles in combination followed by single agent
• None of the above